155 related articles for article (PubMed ID: 26640147)
1. Identification and analysis of CXCR4-positive synovial sarcoma-initiating cells.
Kimura T; Wang L; Tabu K; Tsuda M; Tanino M; Maekawa A; Nishihara H; Hiraga H; Taga T; Oda Y; Tanaka S
Oncogene; 2016 Jul; 35(30):3932-43. PubMed ID: 26640147
[TBL] [Abstract][Full Text] [Related]
2. The CD133+ subpopulation of the SW982 human synovial sarcoma cell line exhibits cancer stem-like characteristics.
Liu A; Feng B; Gu W; Cheng X; Tong T; Zhang H; Hu Y
Int J Oncol; 2013 Apr; 42(4):1399-407. PubMed ID: 23416969
[TBL] [Abstract][Full Text] [Related]
3. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of expression of cancer stem cell markers and fusion gene in synovial sarcoma: Insights into histogenesis and pathogenesis.
Zhou Y; Chen D; Qi Y; Liu R; Li S; Zou H; Lan J; Ju X; Jiang J; Liang W; Shen Y; Pang L; Li F
Oncol Rep; 2017 Jun; 37(6):3351-3360. PubMed ID: 28498445
[TBL] [Abstract][Full Text] [Related]
5. Synovial sarcoma is a stem cell malignancy.
Naka N; Takenaka S; Araki N; Miwa T; Hashimoto N; Yoshioka K; Joyama S; Hamada K; Tsukamoto Y; Tomita Y; Ueda T; Yoshikawa H; Itoh K
Stem Cells; 2010 Jul; 28(7):1119-31. PubMed ID: 20518020
[TBL] [Abstract][Full Text] [Related]
6. CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.
Gassenmaier M; Chen D; Buchner A; Henkel L; Schiemann M; Mack B; Schendel DJ; Zimmermann W; Pohla H
Stem Cells; 2013 Aug; 31(8):1467-76. PubMed ID: 23630186
[TBL] [Abstract][Full Text] [Related]
7. Twist1 is essential in maintaining mesenchymal state and tumor-initiating properties in synovial sarcoma.
Lee KW; Lee NK; Ham S; Roh TY; Kim SH
Cancer Lett; 2014 Feb; 343(1):62-73. PubMed ID: 24051309
[TBL] [Abstract][Full Text] [Related]
8. SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.
Trautmann M; Sievers E; Aretz S; Kindler D; Michels S; Friedrichs N; Renner M; Kirfel J; Steiner S; Huss S; Koch A; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Waha A; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Oncogene; 2014 Oct; 33(42):5006-16. PubMed ID: 24166495
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
[TBL] [Abstract][Full Text] [Related]
10. miR‑494.3p expression in synovial sarcoma: Role of CXCR4 as a potential target gene.
Pazzaglia L; Pollino S; Vitale M; Bientinesi E; Benini S; Ferrari C; Palmerini E; Gambarotti M; Picci P; Benassi MS
Int J Oncol; 2019 Jan; 54(1):361-369. PubMed ID: 30431073
[TBL] [Abstract][Full Text] [Related]
11. Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.
Sand LGL; Buckle T; van Leeuwen FWB; Corver WE; Kruisselbrink AB; Jochemsen AG; Hogendoorn PCW; Szuhai K
BMC Cancer; 2017 May; 17(1):383. PubMed ID: 28549419
[TBL] [Abstract][Full Text] [Related]
12. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma.
Kawai A; Woodruff J; Healey JH; Brennan MF; Antonescu CR; Ladanyi M
N Engl J Med; 1998 Jan; 338(3):153-60. PubMed ID: 9428816
[TBL] [Abstract][Full Text] [Related]
13. Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation.
Allander SV; Illei PB; Chen Y; Antonescu CR; Bittner M; Ladanyi M; Meltzer PS
Am J Pathol; 2002 Nov; 161(5):1587-95. PubMed ID: 12414507
[TBL] [Abstract][Full Text] [Related]
14. The classic prognostic factors tumor stage, tumor size, and tumor grade are the strongest predictors of outcome in synovial sarcoma: no role for SSX fusion type or ezrin expression.
ten Heuvel SE; Hoekstra HJ; Bastiaannet E; Suurmeijer AJ
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):189-95. PubMed ID: 18997619
[TBL] [Abstract][Full Text] [Related]
15. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of FOXM1 expression and antitumor effect of FOXM1 inhibition in synovial sarcomas.
Maekawa A; Kohashi K; Kuda M; Iura K; Ishii T; Endo M; Nakatsura T; Iwamoto Y; Oda Y
BMC Cancer; 2016 Jul; 16():511. PubMed ID: 27439614
[TBL] [Abstract][Full Text] [Related]
17. Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.
Iura K; Maekawa A; Kohashi K; Ishii T; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Harimaya K; Iwamoto Y; Oda Y
Hum Pathol; 2017 Mar; 61():130-139. PubMed ID: 27993576
[TBL] [Abstract][Full Text] [Related]
18. Specificity of TLE1 expression in unclassified high-grade sarcomas for the diagnosis of synovial sarcoma.
Valente AL; Tull J; Zhang S
Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):408-13. PubMed ID: 23197007
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of TLE1 as a diagnostic immunohistochemical marker in synovial sarcoma.
Jagdis A; Rubin BP; Tubbs RR; Pacheco M; Nielsen TO
Am J Surg Pathol; 2009 Dec; 33(12):1743-51. PubMed ID: 19809272
[TBL] [Abstract][Full Text] [Related]
20. [Roles of immunohistochemistry and detection of SYT-SSX fusion gene in diagnosis of synovial sarcoma].
Sun Y; Sun BC; Zhao XL; Wang J; Chen J; Li XQ; Feng YM; Fang ZW; Hao XS
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):480-4. PubMed ID: 17845763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
